Dual immunotherapy shows promising activity in high-risk early-stage HER2-negative breast cancer

Medical Xpress

A combination of two immunotherapy drugs showed encouraging activity when added to standard chemotherapy given before surgery for patients with high-risk, early-stage HER2-negative breast cancer, according to Phase II clinical trial results from the ongoing I-SPY2 clinical trial platform. ...

전문 보기

이 뉴스, 어떠셨어요?

탭 한 번으로 반응 · 로그인 불필요

Dual immunotherapy shows promising activity in high-risk early-stage HER2-negative breast cancer

이 뉴스, 어떠셨어요?

관련 뉴스

'science' 카테고리 뉴스

Ad ASTRA Community Workshop Detailed Schedule & Abstracts

Newly discovered microprotein linked to type 2 diabetes, shows promise as a precision treatment

Image: Starburst galaxy Centaurus A

Medical Xpress의 다른 기사

Immune navigation system discovery could lead to better treatments for chronic inflammation

ICU design guidelines highlight how hospital environments shape patient care and safety

Preeclampsia rates in minority communities shed light on the social roots of maternal health disparities